HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis.

Abstract
The matrix metalloproteinase matrilysin (MMP-7) has been demonstrated to contribute to tumor development. We have shown previously that members of the TNF family of apoptosis-inducing proteins are substrates for this enzyme, resulting in increased death pathway signaling. The goal of the current study was to reconcile the proapoptotic and tumor-promoting functions of matrilysin. In the human HBL100 and murine NMuMG cell lines that represent early stages of tumor progression and that express both Fas ligand and its receptor, exposure to matrilysin results in cell death that can be blocked by FasL neutralizing antibodies. Constitutive expression of matrilysin in these cell lines selects for cells with reduced sensitivity to Fas-mediated apoptosis as demonstrated both with a receptor-activating antibody and with in vitro activated splenocytes. Matrilysin-expressing cells are also significantly less sensitive to chemical inducers of apoptosis. We propose that the expression of matrilysin that has been reported at early stages in various tumor types can act to select cells with a significantly decreased chance of removal due to immune surveillance. As a result, these cells are more likely to acquire additional genetic modifications and develop further as tumors.
AuthorsB Fingleton, T Vargo-Gogola, H C Crawford, L M Matrisian
JournalNeoplasia (New York, N.Y.) (Neoplasia) 2001 Nov-Dec Vol. 3 Issue 6 Pg. 459-68 ISSN: 1522-8002 [Print] United States
PMID11774028 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibodies, Monoclonal
  • Antigens, CD95
  • DNA, Complementary
  • Enzyme Inhibitors
  • FASLG protein, human
  • Fas Ligand Protein
  • Fasl protein, mouse
  • Interleukin-2
  • Membrane Glycoproteins
  • Protein Synthesis Inhibitors
  • Recombinant Fusion Proteins
  • Tnfsf6 protein, rat
  • Concanavalin A
  • Mitomycin
  • Cycloheximide
  • Matrix Metalloproteinase 7
  • Staurosporine
Topics
  • Animals
  • Antibodies, Monoclonal (pharmacology)
  • Antigens, CD95 (physiology)
  • Apoptosis (physiology)
  • Breast (cytology)
  • Clone Cells (cytology, drug effects, enzymology)
  • Concanavalin A (pharmacology)
  • Cycloheximide (pharmacology)
  • DNA, Complementary (genetics)
  • Enzyme Induction
  • Enzyme Inhibitors (pharmacology)
  • Epithelial Cells (cytology, drug effects, enzymology)
  • Fas Ligand Protein
  • Female
  • Humans
  • Interleukin-2 (pharmacology)
  • Killer Cells, Natural (immunology)
  • Lymphocyte Activation (drug effects)
  • Male
  • Mammary Glands, Animal (cytology)
  • Matrix Metalloproteinase 7 (genetics, physiology)
  • Membrane Glycoproteins (antagonists & inhibitors, pharmacology, physiology)
  • Mice
  • Mitomycin (pharmacology)
  • Protein Synthesis Inhibitors (pharmacology)
  • Rabbits
  • Rats
  • Recombinant Fusion Proteins (physiology)
  • Spleen (cytology)
  • Staurosporine (pharmacology)
  • T-Lymphocytes (drug effects, immunology)
  • Transfection

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: